Global Cell Therapy Market Size, Status and Forecast 2019-2025

2 Global Cell Therapy Quarterly Market Size Analysis

• 2.1 Cell Therapy Business Impact Assessment - COVID-19
  • 2.1.1 Global Cell Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Cell Therapy Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Cell Therapy Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Cell Therapy Headquarters and Area Served
• 3.3 Date of Key Players Enter into Cell Therapy Market
• 3.4 Key Players Cell Therapy Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Cell Therapy Segments, By Type

• 4.1 Introduction
  • 1.4.1 Autologous
  • 1.4.2 Allogeneic
• 4.2 By Type, Global Cell Therapy Market Size, 2019-2021

5 Impact of Covid-19 on Cell Therapy Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospitals and clinics
  • 5.5.2 ASCs
  • 5.5.3 Regenerative medicine centers
• 5.2 By Application, Global Cell Therapy Market Size, 2019-2021
  • 5.2.1 By Application, Global Cell Therapy Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Dendreon
  • 7.1.1 Dendreon Business Overview
  • 7.1.2 Dendreon Cell Therapy Quarterly Revenue, 2020
  • 7.1.3 Dendreon Cell Therapy Product Introduction
  • 7.1.4 Dendreon Response to COVID-19 and Related Developments
• 7.2 Mesoblast
  • 7.2.1 Mesoblast Business Overview
  • 7.2.2 Mesoblast Cell Therapy Quarterly Revenue, 2020
  • 7.2.3 Mesoblast Cell Therapy Product Introduction
  • 7.2.4 Mesoblast Response to COVID-19 and Related Developments
• 7.3 Vericel
  • 7.3.1 Vericel Business Overview
  • 7.3.2 Vericel Cell Therapy Quarterly Revenue, 2020
  • 7.3.3 Vericel Cell Therapy Product Introduction
  • 7.3.4 Vericel Response to COVID-19 and Related Developments
• 7.4 Novartis AG
  • 7.4.1 Novartis AG Business Overview
  • 7.4.2 Novartis AG Cell Therapy Quarterly Revenue, 2020
  • 7.4.3 Novartis AG Cell Therapy Product Introduction
  • 7.4.4 Novartis AG Response to COVID-19 and Related Developments
• 7.5 GlaxoSmithKline plc
  • 7.5.1 GlaxoSmithKline plc Business Overview
  • 7.5.2 GlaxoSmithKline plc Cell Therapy Quarterly Revenue, 2020
  • 7.5.3 GlaxoSmithKline plc Cell Therapy Product Introduction
  • 7.5.4 GlaxoSmithKline plc Response to COVID-19 and Related Developments
• 7.6 MEDIPOST
  • 7.6.1 MEDIPOST Business Overview
  • 7.6.2 MEDIPOST Cell Therapy Quarterly Revenue, 2020
  • 7.6.3 MEDIPOST Cell Therapy Product Introduction
  • 7.6.4 MEDIPOST Response to COVID-19 and Related Developments
• 7.7 Osiris
  • 7.7.1 Osiris Business Overview
  • 7.7.2 Osiris Cell Therapy Quarterly Revenue, 2020
  • 7.7.3 Osiris Cell Therapy Product Introduction
  • 7.7.4 Osiris Response to COVID-19 and Related Developments
• 7.8 PHARMICELL
  • 7.8.1 PHARMICELL Business Overview
  • 7.8.2 PHARMICELL Cell Therapy Quarterly Revenue, 2020
  • 7.8.3 PHARMICELL Cell Therapy Product Introduction
  • 7.8.4 PHARMICELL Response to COVID-19 and Related Developments
• 7.9 NuVasive, Inc.
  • 7.9.1 NuVasive, Inc. Business Overview
  • 7.9.2 NuVasive, Inc. Cell Therapy Quarterly Revenue, 2020
  • 7.9.3 NuVasive, Inc. Cell Therapy Product Introduction
  • 7.9.4 NuVasive, Inc. Response to COVID-19 and Related Developments
• 7.10 JCR Pharmaceuticals Co., Ltd
  • 7.10.1 JCR Pharmaceuticals Co., Ltd Business Overview
  • 7.10.2 JCR Pharmaceuticals Co., Ltd Cell Therapy Quarterly Revenue, 2020
  • 7.10.3 JCR Pharmaceuticals Co., Ltd Cell Therapy Product Introduction
  • 7.10.4 JCR Pharmaceuticals Co., Ltd Response to COVID-19 and Related Developments
• 7.11 ANTEROGEN.CO.,LTD.
  • 7.11.1 ANTEROGEN.CO.,LTD. Business Overview
  • 7.11.2 ANTEROGEN.CO.,LTD. Cell Therapy Quarterly Revenue, 2020
  • 7.11.3 ANTEROGEN.CO.,LTD. Cell Therapy Product Introduction
  • 7.11.4 ANTEROGEN.CO.,LTD. Response to COVID-19 and Related Developments
• 7.12 Cynata
  • 7.12.1 Cynata Business Overview
  • 7.12.2 Cynata Cell Therapy Quarterly Revenue, 2020
  • 7.12.3 Cynata Cell Therapy Product Introduction
  • 7.12.4 Cynata Response to COVID-19 and Related Developments
• 7.13 CELLECTIS
  • 7.13.1 CELLECTIS Business Overview
  • 7.13.2 CELLECTIS Cell Therapy Quarterly Revenue, 2020
  • 7.13.3 CELLECTIS Cell Therapy Product Introduction
  • 7.13.4 CELLECTIS Response to COVID-19 and Related Developments
• 7.14 BioNTech IMFS
  • 7.14.1 BioNTech IMFS Business Overview
  • 7.14.2 BioNTech IMFS Cell Therapy Quarterly Revenue, 2020
  • 7.14.3 BioNTech IMFS Cell Therapy Product Introduction
  • 7.14.4 BioNTech IMFS Response to COVID-19 and Related Developments
• 7.15 EUFETS GmbH
  • 7.15.1 EUFETS GmbH Business Overview
  • 7.15.2 EUFETS GmbH Cell Therapy Quarterly Revenue, 2020
  • 7.15.3 EUFETS GmbH Cell Therapy Product Introduction
  • 7.15.4 EUFETS GmbH Response to COVID-19 and Related Developments
• 7.16 Cognate
  • 7.16.1 Cognate Business Overview
  • 7.16.2 Cognate Cell Therapy Quarterly Revenue, 2020
  • 7.16.3 Cognate Cell Therapy Product Introduction
  • 7.16.4 Cognate Response to COVID-19 and Related Developments
• 7.17 Pluristem
  • 7.17.1 Pluristem Business Overview
  • 7.17.2 Pluristem Cell Therapy Quarterly Revenue, 2020
  • 7.17.3 Pluristem Cell Therapy Product Introduction
  • 7.17.4 Pluristem Response to COVID-19 and Related Developments
• 7.18 Grupo Praxis
  • 7.18.1 Grupo Praxis Business Overview
  • 7.18.2 Grupo Praxis Cell Therapy Quarterly Revenue, 2020
  • 7.18.3 Grupo Praxis Cell Therapy Product Introduction
  • 7.18.4 Grupo Praxis Response to COVID-19 and Related Developments
• 7.19 Genzyme Corporation
  • 7.19.1 Genzyme Corporation Business Overview
  • 7.19.2 Genzyme Corporation Cell Therapy Quarterly Revenue, 2020
  • 7.19.3 Genzyme Corporation Cell Therapy Product Introduction
  • 7.19.4 Genzyme Corporation Response to COVID-19 and Related Developments
• 7.20 Advanced Tissue
  • 7.20.1 Advanced Tissue Business Overview
  • 7.20.2 Advanced Tissue Cell Therapy Quarterly Revenue, 2020
  • 7.20.3 Advanced Tissue Cell Therapy Product Introduction
  • 7.20.4 Advanced Tissue Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US